{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T19:04:26Z","timestamp":1782759866079,"version":"3.54.5"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023QH310"],"award-info":[{"award-number":["ZR2023QH310"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023QH310"],"award-info":[{"award-number":["ZR2023QH310"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203766"],"award-info":[{"award-number":["82203766"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Research Foundation of Shandong University","award":["2020SDUCRCA018"],"award-info":[{"award-number":["2020SDUCRCA018"]}]},{"name":"Clinical Research Foundation of Shandong University","award":["2020SDUCRCA018"],"award-info":[{"award-number":["2020SDUCRCA018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04227-4","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T23:24:23Z","timestamp":1770161063000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["ERBB2 I655V mutation correlates with efficacy of immunotherapy in gallbladder cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Qiang","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-nan","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zong-li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang-shuai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"issue":"1","key":"4227_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-022-00398-y","volume":"8","author":"JC Roa","year":"2022","unstructured":"Roa JC, Garcia P, Kapoor VK, Maithel SK, Javle M, Koshiol J. Gallbladder cancer. Nat Rev Dis Primers. 2022;8(1):69.","journal-title":"Nat Rev Dis Primers"},{"issue":"22","key":"4227_CR2","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.3748\/wjg.v23.i22.3978","volume":"23","author":"A Sharma","year":"2017","unstructured":"Sharma A, Sharma KL, Gupta A, Yadav A, Kumar A. Gallbladder cancer epidemiology, pathogenesis and molecular genetics: recent update. World J Gastroenterol. 2017;23(22):3978\u201398.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"4227_CR3","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1080\/00325481.2024.2345585","volume":"136","author":"Y Sun","year":"2024","unstructured":"Sun Y, Gong J, Li Z, Han L, Sun D. Gallbladder cancer: surgical treatment, immunotherapy, and targeted therapy. Postgrad Med. 2024;136(3):278\u201391.","journal-title":"Postgrad Med"},{"issue":"3","key":"4227_CR4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ctrv.2015.01.003","volume":"41","author":"C Bizama","year":"2015","unstructured":"Bizama C, Garcia P, Espinoza JA, Weber H, Leal P, Nervi B, et al. Targeting specific molecular pathways holds promise for advanced gallbladder cancer therapy. Cancer Treat Rev. 2015;41(3):222\u201334.","journal-title":"Cancer Treat Rev"},{"key":"4227_CR5","doi-asserted-by":"publisher","first-page":"113564","DOI":"10.1016\/j.ejca.2024.113564","volume":"199","author":"BH Ten Haaft","year":"2024","unstructured":"Ten Haaft BH, Pedregal M, Prato J, Klumpen HJ, Moreno V, Lamarca A. Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: current advancements and future perspectives. Eur J Cancer. 2024;199:113564.","journal-title":"Eur J Cancer"},{"issue":"5","key":"4227_CR6","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.ccell.2018.09.010","volume":"34","author":"KB Pahuja","year":"2018","unstructured":"Pahuja KB, Nguyen TT, Jaiswal BS, Prabhash K, Thaker TM, Senger K, et al. Actionable activating oncogenic ERBB2\/HER2 transmembrane and juxtamembrane domain mutations. Cancer Cell. 2018;34(5):792\u2013806. e5.","journal-title":"Cancer Cell"},{"issue":"11","key":"4227_CR7","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.annonc.2022.08.001","volume":"33","author":"JE Augustin","year":"2022","unstructured":"Augustin JE, Soussan P, Bass AJ. Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma. Ann Oncol. 2022;33(11):1134\u201348.","journal-title":"Ann Oncol"},{"issue":"20","key":"4227_CR8","doi-asserted-by":"publisher","first-page":"8286","DOI":"10.1158\/0008-5472.CAN-07-6316","volume":"68","author":"JK Miller","year":"2008","unstructured":"Miller JK, Shattuck DL, Ingalla EQ, Yen L, Borowsky AD, Young LJ, et al. Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer. Cancer Res. 2008;68(20):8286\u201394.","journal-title":"Cancer Res"},{"issue":"19","key":"4227_CR9","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1002\/cncr.33102","volume":"126","author":"S Kunte","year":"2020","unstructured":"Kunte S, Abraham J, Montero AJ. Novel HER2-targeted therapies for HER2-positive metastatic breast cancer. Cancer. 2020;126(19):4278\u201388.","journal-title":"Cancer"},{"issue":"9","key":"4227_CR10","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41571-024-00924-9","volume":"21","author":"J Yoon","year":"2024","unstructured":"Yoon J, Oh DY. HER2-targeted therapies beyond breast cancer - an update. Nat Rev Clin Oncol. 2024;21(9):675\u2013700.","journal-title":"Nat Rev Clin Oncol"},{"issue":"W1","key":"4227_CR11","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"48","author":"T Li","year":"2020","unstructured":"Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509\u201314.","journal-title":"Nucleic Acids Res"},{"key":"4227_CR12","doi-asserted-by":"publisher","unstructured":"Giannis D, Cerullo M, Moris D, Shah KN, Herbert G, Zani S, et al. Validation of the 8th edition American Joint Commission on Cancer (AJCC) gallbladder cancer staging system: prognostic discrimination and identification of key predictive factors. Cancers (Basel). 2021;13(3):547. https:\/\/doi.org\/10.3390\/cancers13030547.","DOI":"10.3390\/cancers13030547"},{"issue":"12","key":"4227_CR13","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1111\/jcmm.12662","volume":"19","author":"Z Sun","year":"2015","unstructured":"Sun Z, Shi Y, Shen Y, Cao L, Zhang W, Guan X. Analysis of different HER-2 mutations in breast cancer progression and drug resistance. J Cell Mol Med. 2015;19(12):2691\u2013701.","journal-title":"J Cell Mol Med"},{"issue":"6","key":"4227_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1155\/2013\/587682","volume":"34","author":"NR AbdRaboh","year":"2013","unstructured":"AbdRaboh NR, Shehata HH, Ahmed MB, Bayoumi FA. HER1 R497K and HER2 I655V polymorphisms are linked to development of breast cancer. Dis Markers. 2013;34(6):407\u201317.","journal-title":"Dis Markers"},{"issue":"10","key":"4227_CR15","first-page":"1109","volume":"12","author":"KG Montgomery","year":"2003","unstructured":"Montgomery KG, Gertig DM, Baxter SW, Milne RL, Dite GS, McCredie MR, et al. The HER2 I655V polymorphism and risk of breast cancer in women\u2009<\u2009age 40 years. Cancer Epidemiol Biomarkers Prev. 2003;12(10):1109\u201311.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"4227_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/01.cej.0000130015.91525.c7","volume":"13","author":"D Pinto","year":"2004","unstructured":"Pinto D, Vasconcelos A, Costa S, Pereira D, Rodrigues H, Lopes C, et al. HER2 polymorphism and breast cancer risk in Portugal. Eur J Cancer Prev. 2004;13(3):177\u201381.","journal-title":"Eur J Cancer Prev"},{"issue":"20","key":"4227_CR17","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1093\/jnci\/94.20.1581","volume":"94","author":"KY Chan","year":"2002","unstructured":"Chan KY, Cheung AN, Yip SP, Ko HH, Lai TW, Khoo US. Population-based case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst. 2002;94(20):1581\u20132.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"4227_CR18","first-page":"49","volume":"53","author":"P Zubor","year":"2006","unstructured":"Zubor P, Vojvodova A, Danko J, Kajo K, Szunyogh N, Lasabova Z, et al. HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a population-based case-control study in Slovakia. Neoplasma. 2006;53(1):49\u201355.","journal-title":"Neoplasma"},{"issue":"8","key":"4227_CR19","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1245\/s10434-009-0538-x","volume":"16","author":"MT Hueman","year":"2009","unstructured":"Hueman MT, Vollmer CM Jr., Pawlik TM. Evolving treatment strategies for gallbladder cancer. Ann Surg Oncol. 2009;16(8):2101\u201315.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"4227_CR20","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1016\/j.surg.2020.12.039","volume":"169","author":"M Chen","year":"2021","unstructured":"Chen M, Cao J, Xiang Y, Ma X, Bai Y, Lai Q, et al. Hepatectomy strategy for T2 gallbladder cancer between segment IVb and V resection and wedge resection: a propensity score-matched study. Surgery. 2021;169(6):1304\u201311.","journal-title":"Surgery"},{"issue":"4","key":"4227_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.21037\/cco.2019.07.05","volume":"8","author":"AA Azizi","year":"2019","unstructured":"Azizi AA, Lamarca A, Valle JW. Systemic therapy of gallbladder cancer: review of first line, maintenance, neoadjuvant and second line therapy specific to gallbladder cancer. Chin Clin Oncol. 2019;8(4):43.","journal-title":"Chin Clin Oncol"},{"issue":"9","key":"4227_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.6004\/jnccn.2025.0042","volume":"23","author":"AB Benson","year":"2025","unstructured":"Benson AB 3rd, D\u2019Angelica MI, Abrams T, Ahmed A, Akce M, Anaya DA, et al. Biliary tract Cancers, version 2.2025, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2025;23(9):403\u201318.","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"4227_CR23","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41419-020-02749-7","volume":"11","author":"F Song","year":"2020","unstructured":"Song F, Hu B, Cheng JW, Sun YF, Zhou KQ, Wang PX, et al. Anlotinib suppresses tumor progression via blocking the VEGFR2\/PI3K\/AKT cascade in intrahepatic cholangiocarcinoma. Cell Death Dis. 2020;11(7):573.","journal-title":"Cell Death Dis"},{"issue":"11","key":"4227_CR24","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","volume":"4","author":"B Han","year":"2018","unstructured":"Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 2018;4(11):1569\u201375.","journal-title":"JAMA Oncol"},{"issue":"7","key":"4227_CR25","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1158\/1078-0432.CCR-24-2531","volume":"31","author":"C Wang","year":"2025","unstructured":"Wang C, Hu X, Yang L, Xu Y, Zheng B, Yang J, et al. Anlotinib versus placebo as adjuvant therapy for localized High-Grade Soft-Tissue sarcomas: a phase II, double-blinded, randomized controlled trial. Clin Cancer Res. 2025;31(7):1194\u2013203.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"4227_CR26","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/jama.2021.12836","volume":"326","author":"H Luo","year":"2021","unstructured":"Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA. 2021;326(10):916\u201325.","journal-title":"JAMA"},{"issue":"4","key":"4227_CR27","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S1470-2045(20)30011-5","volume":"21","author":"S Qin","year":"2020","unstructured":"Qin S, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020;21(4):571\u201380.","journal-title":"Lancet Oncol"},{"issue":"6","key":"4227_CR28","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","volume":"21","author":"J Huang","year":"2020","unstructured":"Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, et al. Camrelizumab versus investigator\u2019s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020;21(6):832\u201342.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4227_CR29","doi-asserted-by":"publisher","first-page":"22275","DOI":"10.1038\/s41598-025-06625-2","volume":"15","author":"M Xu","year":"2025","unstructured":"Xu M, Pu Y, Jiang Y, Liu Y, Feng Y, Zhao X, et al. Anlotinib plus camrelizumab and chemotherapy as first-line treatment in patients with advanced esophageal squamous cell carcinoma. Sci Rep. 2025;15(1):22275.","journal-title":"Sci Rep"},{"key":"4227_CR30","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.lungcan.2021.08.006","volume":"160","author":"N Zhou","year":"2021","unstructured":"Zhou N, Jiang M, Li T, Zhu J, Liu K, Hou H, et al. Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: an open-label, dose escalation and expansion study. Lung Cancer. 2021;160:111\u20137.","journal-title":"Lung Cancer"},{"issue":"9","key":"4227_CR31","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","volume":"52","author":"WS Lee","year":"2020","unstructured":"Lee WS, Yang H, Chon HJ, Kim C. Combination of anti-angiogenic therapy and immune checkpoint Blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med. 2020;52(9):1475\u201385.","journal-title":"Exp Mol Med"},{"key":"4227_CR32","doi-asserted-by":"publisher","unstructured":"Uckun FM, Qazi S. Upregulated expression of ERBB2\/HER2 in multiple myeloma as a predictor of poor survival outcomes. Int J Mol Sci. 2023;24(12):9943. https:\/\/doi.org\/10.3390\/ijms24129943.","DOI":"10.3390\/ijms24129943"},{"issue":"5","key":"4227_CR33","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.jhep.2021.06.023","volume":"75","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zuo C, Liu L, Hu Y, Yang B, Qiu S, et al. Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in erbb pathway-mutated gallbladder cancer. J Hepatol. 2021;75(5):1128\u201341.","journal-title":"J Hepatol"},{"issue":"1","key":"4227_CR34","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41392-020-00324-2","volume":"5","author":"X Song","year":"2020","unstructured":"Song X, Hu Y, Li Y, Shao R, Liu F, Liu Y. Overview of current targeted therapy in gallbladder cancer. Signal Transduct Target Ther. 2020;5(1):230.","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"4227_CR35","doi-asserted-by":"publisher","first-page":"6950","DOI":"10.1074\/jbc.M709202200","volume":"283","author":"EV Bocharov","year":"2008","unstructured":"Bocharov EV, Mineev KS, Volynsky PE, Ermolyuk YS, Tkach EN, Sobol AG, et al. Spatial structure of the dimeric transmembrane domain of the growth factor receptor ErbB2 presumably corresponding to the receptor active state. J Biol Chem. 2008;283(11):6950\u20136.","journal-title":"J Biol Chem"},{"issue":"2","key":"4227_CR36","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.jmb.2010.05.016","volume":"400","author":"KS Mineev","year":"2010","unstructured":"Mineev KS, Bocharov EV, Pustovalova YE, Bocharova OV, Chupin VV, Arseniev AS. Spatial structure of the transmembrane domain heterodimer of ErbB1 and ErbB2 receptor tyrosine kinases. J Mol Biol. 2010;400(2):231\u201343.","journal-title":"J Mol Biol"},{"issue":"25","key":"4227_CR37","doi-asserted-by":"publisher","first-page":"15937","DOI":"10.1073\/pnas.252640799","volume":"99","author":"SJ Fleishman","year":"2002","unstructured":"Fleishman SJ, Schlessinger J, Ben-Tal N. A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci U S A. 2002;99(25):15937\u201340.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"4227_CR38","doi-asserted-by":"publisher","first-page":"113343","DOI":"10.1016\/j.celrep.2023.113343","volume":"42","author":"Y Liu","year":"2023","unstructured":"Liu Y, Peng Y, Du W, Yu C, Peng Z, Qin L, et al. PD-L1-mediated immune evasion in triple-negative breast cancer is linked to the loss of ZNF652. Cell Rep. 2023;42(11):113343.","journal-title":"Cell Rep"},{"issue":"5","key":"4227_CR39","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","volume":"38","author":"F Dammeijer","year":"2020","unstructured":"Dammeijer F, van Gulijk M, Mulder EE, Lukkes M, Klaase L, van den Bosch T, et al. The PD-1\/PD-L1-Checkpoint restrains T cell immunity in Tumor-Draining lymph nodes. Cancer Cell. 2020;38(5):685\u2013700. e8.","journal-title":"Cancer Cell"},{"issue":"4","key":"4227_CR40","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/15384047.2016.1156256","volume":"17","author":"M Ji","year":"2016","unstructured":"Ji M, Liu Y, Li Q, Li X, Ning Z, Zhao W, et al. PD-1\/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR\/KRAS mutations. Cancer Biol Ther. 2016;17(4):407\u201313.","journal-title":"Cancer Biol Ther"},{"issue":"12","key":"4227_CR41","doi-asserted-by":"publisher","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","volume":"23","author":"ZY Dong","year":"2017","unstructured":"Dong ZY, Zhong WZ, Zhang XC, Su J, Xie Z, Liu SY, et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 Blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res. 2017;23(12):3012\u201324.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4227_CR42","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1136\/gutjnl-2018-316039","volume":"68","author":"M Li","year":"2019","unstructured":"Li M, Liu F, Zhang F, Zhou W, Jiang X, Yang Y, et al. Genomic ERBB2\/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis. Gut. 2019;68(6):1024\u201333.","journal-title":"Gut"},{"issue":"4","key":"4227_CR43","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.gpb.2021.08.001","volume":"19","author":"T Chen","year":"2021","unstructured":"Chen T, Chen X, Zhang S, Zhu J, Tang B, Wang A, et al. The genome sequence archive family: toward explosive data growth and diverse data types. Genomics Proteom Bioinf. 2021;19(4):578\u201383.","journal-title":"Genomics Proteom Bioinf"},{"issue":"D1","key":"4227_CR44","doi-asserted-by":"publisher","first-page":"D27","DOI":"10.1093\/nar\/gkab951","volume":"50","author":"C-N Members","year":"2022","unstructured":"Members C-N, Partners. Database resources of the National genomics data center, China National center for bioinformation in 2022. Nucleic Acids Res. 2022;50(D1):D27\u201338.","journal-title":"Nucleic Acids Res"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04227-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04227-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04227-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:03:04Z","timestamp":1772798584000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04227-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4227"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04227-4","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]},"assertion":[{"value":"17 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Research Ethics Committee of Qilu Hospital of Shandong University (KYLL-202011-077). The research was conducted in accordance with the Declarations of Helsinki and Istanbul. Written informed consent was obtained from the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication has been obtained from all authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"110"}}